PLGA Microsphere Formulation for Sustained GnRH Antagonist Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GnRH antagonist formulations have limited duration of action, necessitating the development of long-acting controlled or extended release formulations to achieve sustained therapeutic effects for conditions such as prostate cancer and benign prostatic hyperplasia.
Innovation Solution
A composition comprising cetrorelix and poly-lactic co-glycolic acid (PLGA) polymers with specific lactide:glycolide ratios, forming either hydrogels or microspheres for controlled release, allowing extended release of cetrorelix for 1-6 months with minimal variation and high encapsulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If short-acting GnRH antagonist formulations are used, then immediate suppression of LH and FSH is achieved, but the duration of therapeutic effect is limited requiring frequent administration
Solution Approach 1:
The formulation is segmented into microspheres of different sizes (1-5 μm, 5-10 μm, 10-20 μm) with different release rates, allowing simultaneous achievement of rapid initial release (from smaller microspheres) and prolonged sustained release (from larger microspheres), resolving the contradiction between fast onset and long duration
Solution Approach 2:
The patent uses PLGA polymers with different lactide:glycolide ratios (50:50 to 100:0) to control the degradation rate and release profile. By adjusting this compositional parameter, the formulation achieves both rapid initial release and extended therapeutic effect lasting 1-6 months
2Duration of action of moving object
If long-acting depot formulations are developed, then duration of therapeutic effect is extended, but manufacturing complexity and formulation development difficulty increase
Solution Approach 1:
The patent employs composite PLGA polymers combining different lactide:glycolide ratios to create a single formulation system that provides both rapid and sustained release. This composite approach simplifies manufacturing compared to using multiple separate formulations, while achieving extended duration of action
Solution Approach 2:
The PLGA microsphere system serves multiple functions simultaneously: it provides rapid initial release for immediate therapeutic effect, sustained release for prolonged duration, and controlled degradation for predictable release profiles. This multi-functionality reduces the need for multiple separate formulation systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves a therapeutic effect within 24 hours and maintains therapeutic levels for at least 90 days in over 95% of treated patients, providing consistent and prolonged release of cetrorelix with reduced variation and high integrity over the release duration.
Implementation Method 1
said polymer comprising a poly-lactic co-glycolic acid (PLGA) in a lactide: glycolide molar ratio between 50:50 and 100:0
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists, and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.